AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Deciding between AbbVie Inc. (NYSE:ABBV) and Eli Lilly & Co. (NYSE:LLY) requires balancing reliable dividend growth against high-octane metabolic drug expansion. Both companies lead the healthcare sector, but their current paths offer very different investor profiles.
AbbVie has pivoted from its legacy blockbuster Humira to a new generation of immunology and oncology treatments. Eli Lilly focuses on the massive market demand for diabetes and weight-loss medications. Investors often compare these two because they represent the largest players in the pharmaceutical industry, each presenting distinct risk-reward scenarios.
AbbVie operates as a global biopharmaceutical leader, focusing on immunology, oncology, and aesthetics. The company distributes products mainly through three major wholesale distributors: McKesson & Co. (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR). Customer concentration like this adds a layer of risk to the business, as these three firms account for nearly all sales in the pharmaceutical stocks category.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.